


Johan Wäborg presenterar Iconovo på Aktiedagen
Iconovo utvecklar och förnyar inhalation av läkemedel och vaccin
Iconovo utvecklar och förnyar inhalation av läkemedel och vaccin. Många…




Invitation to companies in Japan
In July, Måns Österberg, Director Alliance Management will visit our collaboration partners in Japan to develop the projects further. There will also…

Invitation to Korean companies
In April, 2023, Måns Österberg, Director Alliance Management will visit our collaboration partners in Korea to develop the projects further. There will…


Iconovo updates its long-term financial targets – expects strong revenue growth with a high margin
PRESS RELEASE
Iconovo expects to reach sales of SEK 250 million in 2027. The target for the operating profit in the same year is SEK 125 million, resulting…

Iconovo uppdaterar sina långsiktiga finansiella mål – ser stark intäktsökning med hög marginal
PRESSMEDDELANDE
Iconovo tillkännager idag sina femårsmål för verksamheten. År 2027 räknar bolaget med att uppnå en försäljning om 250 miljoner…


Shorter time to market with a customized inhaler platform
In the next few years, the patents will expire for many best-selling inhaled medicines. As for other pharmaceuticals, there is a huge market…
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se
CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se